

OCTOBER 16-19, 2024  
CHICAGO, ILLINOIS



Chicago  
Specials Fall Group Meeting

Barlogie-Salmon Myeloma Committee

# Barlogie-Salmon Myeloma Committee

## Leadership

Chair: ..... Robert Z. Orlowski, MD, PhD  
 Vice-Chair: ..... Sikander Ailawadhi, MD  
 Vice-Chair: ..... Jing Christine Ye, MD, MSc  
 Executive Officer: ..... Susan M. O'Brien, MD  
 Statisticians: ..... Antje Hoering, PhD  
 ..... Rachael Sexton, MS  
 ..... Adam Rosenthal, MS

## Scientific Leadership

Translational Medicine: ..... Brian A. Walker, BSc, PhD  
 Radiation: ..... Chelsea Camille Pinnix, MD, PhD  
 Surgery: ..... TBD  
 Imaging: ..... Eric M. Rohren, MD, PhD  
 Pathology: ..... Pei Lin, MD  
 Early Therapeutics: ..... Frits van Rhee, MD, PhD

## Designates

DEI Champion: ..... Manuel Ricardo Espinoza-Gutarra, MD  
 Digital Engagement: ..... TBD  
 NCORP Representative: ..... Charles S. Kuzma, MD  
 Veterans Affairs: ..... Thomas R. Chauncey, MD, PhD  
 Data Coordinators: ..... Aubrey Gilmore, BA  
 ..... Daria Chugina, MD, CCRPS  
 ..... Pasarlai Ahmadzai, MD, MPH  
 Oncology Research Professionals:  
 CRA: ..... Brandon Richard Labadie, CCRP  
 Nurse: ..... Teresa Witcher, BSN, RN  
 Patient Advocate: ..... Paul Gater, MPhil  
 Pharmaceutical Science: ..... Craig Elg, PharmD  
 ..... Ila M. Saunders, PharmD  
 Protocol Project Manager: ..... Amy Doyle  
 Clinical Trials Program Manager: ..... Sharon Palmer

## Time/Location

Friday, October 18, 2024 7:30 a.m. - 9:30 a.m.  
 Room: Water Tower (Concourse Level, West Tower)

## Active Studies

**S1803**, "Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)." Drs. A. Krishnan and S. Chhabra. Activated: 6/27/19.

**S2005**, "A Phase II Randomized Study Comparing Ibrutinib and Rituximab vs. Venetoclax and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) /Lymphoplasmacytic Lymphoma (LPL)" Drs. S. Ailawadhi and D. Bhutani. Activated: 6/24/21; Closed: 4/8/22; Re-activated: 2/15/24.

**S2209**, "A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Upfront Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd)." Drs. S. Ailawadhi, J.C. Ye, B. Lipe, T. Chauncey, and K. Gowin. Activated 5/30/23.

**S2213**, "Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCD) Induction Followed by Autologous Stem Cell Transplant or D-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis." Drs. P. Hagen, T. Parker, and S. Sidana. Activated 12/1/23

**EEA173**, "Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma." Activated: 4/30/19.

**EEA181**, "Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial." Activated: 10/27/20.

## Closed Studies

**S1211**, "A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)." Drs. S. Usmani, S. Ailawadhi, and B. Lipe. Activated: 11/9/12. Closed: 6/2/16.

**S1702**, "A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis." Drs. T. Parker and V. Sanchorawala. Activated: 3/8/18; Closed: 9/30/19.

**S1304**, "A Phase II Randomized Study Comparing Two Doses of Carfilzomib with Dexamethasone for Relapse/Refractory Multiple Myeloma." Dr. S. Ailawadhi. Activated: 10/18/13. Closed: 11/6/15.

**S0777**, "Frontline Phase III Rev/Dex +/- Vel, no upfront transplant." Dr. B. Durie. Activated: 4/1/18. Closed: 2/2/12.

**S0120**, "A prospective Observational Biologic Study of Asymptomatic Patients with Monoclonal Gammopathy and Plasmaproliferative Disorders." Dr. M. Dhodapkar. Activated: 6/1/02. Closed: 4/1/11.

# Barlogie-Salmon Myeloma Committee

## CTN 0702, "Single Autologous Transplant with or without RVD

Consolidation versus Tandem Transplant and Maintenance Therapy." Dr. G. Somlo. Activated: 2/15/11. Closed: 11/15/13.

A061402, "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone." Dr. A. Kuman Mahindra. Activated: 12/23/15. Closed: 8/15/19.

E1A11, "Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURATION Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)." Drs. S. Kumar, A. Cohen, and J. Zonder. Activated: 11/22/13. Closed: 1/29/19.

E3A06 (was S0909), "High-risk AMM – Revlimid." Dr. M. Dhodopkar. Activated: 1/17/11. Closed: 7/14/17.

A061402, "Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone after Radiation Therapy in Treating Patients with Solitary Plasmacytoma of Bone." Dr. A. Kumar Mahindra. Activated: 12/23/15. Closed: 8/15/19.

EAA171, "Optimizing Prolonged Treatment in Myeloma Using MRD Assessment (OPTIMUM)." Dr. S. Kumar. Activated: 6/1/21. Closed 3/3/23.

## Proposed Studies-Pre-Triage/On Hold

SXXXX, "A Phase II Study of Optimal Induction and MRD Driven Maintenance Therapy for Newly Diagnosed High Risk Multiple Myeloma." Drs. B. Lipe, J.C. Ye, and K. Gowin.

SXXXX, "Phase III Study Evaluating Freedom From Long-term Maintenance for Standard Risk Myeloma Patients Achieving Measurable Residual Disease Negativity." Dr. M. Mohyuddin.

SXXXX, "A Phase II Trial of BCMA Bi-Specific T-Cell Engager (BiTE) Teclistamab in Patients with Systemic Light Chain (AL) Amyloidosis." Drs. D. Bhutani and K. Dorritie.

SXXXX, "An Open-Label Randomized Phase 2 Trial to Incorporate Venetoclax in Early Relapsed t(11;14) Multiple Myeloma." Dr. R. Chakraborty.

SXXXX, "Developing Smoldering Multiple Myeloma Concept." Drs. P. Hagen and A. Cowan.

## Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Spring 2024 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

## Published/Accepted Manuscripts

None this cycle

## Submitted Manuscripts

S0777/S1211 Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis. Banerjee R, Sexton R, Cowan A, Rosenberg A, Ailawadhi S, Rajkumar V, Kumar S, Lonial S, Durie B, Richardson P, Usmani S, Hoering A, Orłowski R. Submitted, 2024.

## Barlogie-Salmon Myeloma Committee

**Accrual from trials that are open as of 6/30/2024 or have closed in the prior 18 Months by Institution and Study**

	S1803	S2209	EAA173	EAA181
Ascension Providence Hospitals - Southfield	2	-	1	-
Banner University Medical Center - Tucson	8	-	-	5
Boston Medical Center	5	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	25	-	5	-
Cancer Research for the Ozarks NCORP	2	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	4	-	-	-
Cedars-Sinai Medical Center	6	-	-	-
City of Hope Comprehensive Cancer Center	110	-	-	-
Columbia University Minority Underserved NCORP	-	1	-	-
Columbus NCI Community Oncology Research Program	5	-	-	-
CommonSpirit Health Research Institute	1	3	-	-
Dayton NCI Community Oncology Research Program	5	-	-	-
Duke University - Duke Cancer Institute LAPS	3	-	-	-
Fred Hutchinson Cancer Research Center LAPS	3	-	8	-
Froedtert and the Medical College of Wisconsin LAPS	11	-	-	-
Georgia NCI Community Oncology Research Program	14	-	-	-
Gulf South Minority Underserved NCORP	4	-	-	-
Heartland Cancer Research NCORP	11	3	-	-
Henry Ford Hospital	-	-	1	-
Houston Methodist Hospital	8	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	47	1	-	-
Lahey Hospital and Medical Center	3	-	-	-
Loyola University Medical Center	24	-	3	1
MU Health Care Goldschmidt Cancer Center	3	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	-	2
Medical University of South Carolina Minority Underserved NCORP	46	-	1	1
Mercy Medical Center - Des Moines	1	-	-	-
Michigan Cancer Research Consortium NCORP	9	-	-	-
Moffitt Cancer Center	42	-	-	-
Montana Cancer Consortium NCORP	4	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	1	-	-

## Barlogie-Salmon Myeloma Committee

Accrual from trials that are open as of 6/30/2024 or have closed in the prior 18 Months by Institution and Study

	S1803	S2209	EAA173	EAA181
Nevada Cancer Research Foundation NCORP	-	-	1	-
New Mexico Minority Underserved NCORP	14	2	-	-
Ohio State University Comprehensive Cancer Center LAPS	5	-	-	-
Oregon Health and Science University	30	-	3	9
Pacific Cancer Research Consortium NCORP	16	3	-	-
Parker Adventist Hospital	2	-	-	-
Riverside Methodist Hospital	3	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	3	-	-	-
Tulane University School of Medicine	-	-	1	-
UC Davis Comprehensive Cancer Center LAPS	23	4	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	12	-	-	-
University of Arkansas for Medical Sciences	-	2	-	2
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	2
University of Kansas Cancer Center - MCA Rural MU NCORP	33	-	-	-
University of Kentucky/Markey Cancer Center	3	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	15	-	-	-
University of Oklahoma Health Sciences Center LAPS	2	-	-	-
University of Rochester LAPS	15	2	-	3
University of Texas Health Science Center at San Antonio	18	-	-	-
University of Texas MD Anderson Cancer Center LAPS	26	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	16	-	4	2
Upstate Carolina Consortium Community Oncology Research Program	4	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	16	-	-	-
Wisconsin NCI Community Oncology Research Program	20	-	-	-
Yale University - Yale Cancer Center LAPS	-	2	4	8
ALLIANCE	200	2	-	-
CCTG	11	-	-	-
ECOG-ACRIN	171	1	-	-
NRG	102	-	-	-
<b>Total</b>	<b>1,166</b>	<b>27</b>	<b>32</b>	<b>35</b>

